title: Thrombotic microangiopathy after living-donor liver re-transplantation.
abstract: Thrombotic microangiopathy (TMA) is a rare but potentially lethal complication encountered in solid organ and bone marrow transplant recipients that requires rapid recognition, diagnosis, and initiation of therapy. Several causes have been identified, including viral infections and various medications. We report a case of TMA after living-donor liver transplantation (LDLT). A 60-year-old man underwent LDLT for end-stage liver disease secondary to hepatitis C virus. After 6 months, he required re-transplantation because graft failure was caused by a small-for-size graft. The immunosuppressive regimen for the second transplantation consisted of tacrolimus and prednisolone; cyclosporine (CsA), mycophenolate mofetil, and prednisolone had been used for the first transplantation. Despite multiple transfusions of packed red blood cells and concentrated platelets, his hemoglobin and platelets decreased and lactate dehydrogenase increased following re-transplantation. Hematological evaluation revealed findings consistent with TMA. As soon as TMA was diagnosed, the calcineurin inhibitor (CNI) was changed from tacrolimus to CsA, and fresh frozen plasma (FFP) was given. The patient's platelets gradually increased after the CNI was changed, and no transfusions were needed. Therefore, tacrolimus was suspected as the cause of the patient's TMA. Early diagnosis, switching CNIs, and FFP supplementation allowed the TMA to resolve without the need for plasma exchange.
authors.affiliation: Department of Anesthesiology and Resuscitology, Okayama University Medical School, 2-5-1 Shikata-cho, Okayama, Okayama, 700-8558, Japan. matusakik@ybb.ne.jp
authors.forename: Takashi
authors.initials: T
authors.lastname: Matsusaki
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Morimatsu
authors.forename: Tetsufumi
authors.initials: T
authors.lastname: Sato
authors.forename: Kenji
authors.initials: K
authors.lastname: Sato
authors.forename: Satoshi
authors.initials: S
authors.lastname: Mizobuchi
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Morita
mesh_terms: D065095:Calcineurin Inhibitors; D006801:Humans; D016031:Liver Transplantation / Q000009:adverse effects*; D019520:Living Donors; D008297:Male; D008875:Middle Aged; D057049:Thrombotic Microangiopathies / Q000188:drug therapy / Q000209:etiology*
chemical_list: D065095:Calcineurin Inhibitors
references.citation: Liver Transpl. 2003 Dec;9(12):1328-33
references.pmid: 14625834
references.citation: J Clin Apher. 1999;14(1):9-13
references.pmid: 10355657
references.citation: Am J Kidney Dis. 1998 Mar;31(3):521-6
references.pmid: 9506691
references.citation: N Engl J Med. 2002 Aug 22;347(8):589-600
references.pmid: 12192020
references.citation: Transplantation. 2005 Jul 27;80(2):169-75
references.pmid: 16041260
references.citation: Transplantation. 2000 Jan 15;69(1):70-5
references.pmid: 10653383
references.citation: J Clin Apher. 2004;19(2):63-5
references.pmid: 15274197
references.citation: Surg Today. 2007;37(4):345-8
references.pmid: 17387572
references.citation: Transplantation. 1999 Mar 15;67(5):702-6
references.pmid: 10096525
references.citation: Transplantation. 1999 Feb 27;67(4):539-44
references.pmid: 10071024